David L Jaye
Overview
Explore the profile of David L Jaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1952
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nair R, Vu A, Vu A, Freer A, Bhatia K, Wang D, et al.
Blood
. 2024 Dec;
145(7):732-747.
PMID: 39693611
We previously demonstrated that reduced intrinsic electron transport chain (ETC) activity predicts and promotes sensitivity to the B-cell lymphoma 2 (BCL-2) antagonist, venetoclax (Ven), in multiple myeloma (MM). Heme, an...
2.
Abro B, Maurer M, Habermann T, Burack W, Chapman J, Cohen J, et al.
Blood
. 2024 Sep;
144(19):2063-2066.
PMID: 39255410
Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that...
3.
Morris A, Sullivan H, Wooten M, Waller E, Jaye D
Am J Clin Pathol
. 2024 May;
162(5):464-470.
PMID: 38767053
Objectives: To determine whether the information provided by short tandem repeat (STR) testing and bone marrow (BM) biopsy specimens following hematopoietic stem cell transplant (HSCT) provides redundant information, leading to...
4.
Daddacha W, Monroe D, Schlafstein A, Withers A, Thompson E, Danelia D, et al.
NAR Cancer
. 2024 Feb;
6(1):zcae007.
PMID: 38406263
Diffuse large B-cell lymphoma (DLBCL) is a commonly diagnosed, aggressive non-Hodgkin's lymphoma. While R-CHOP chemoimmunotherapy is potentially curative, about 40% of DLBCL patients will fail, highlighting the need to identify...
5.
Tavolara T, Khan Niazi M, Feldman A, Jaye D, Flowers C, Cooper L, et al.
Diagn Pathol
. 2024 Jan;
19(1):17.
PMID: 38243330
Background: c-MYC and BCL2 positivity are important prognostic factors for diffuse large B-cell lymphoma. However, manual quantification is subject to significant intra- and inter-observer variability. We developed an automated method...
6.
Cerhan J, Maurer M, Link B, Feldman A, Habermann T, Jaye D, et al.
Am J Hematol
. 2024 Jan;
99(3):408-421.
PMID: 38217361
To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/)....
7.
Kotov D, Lee O, Fattinger S, Langner C, Guillen J, Peters J, et al.
Cell
. 2023 Nov;
186(25):5536-5553.e22.
PMID: 38029747
Mycobacterium tuberculosis (Mtb) causes 1.6 million deaths annually. Active tuberculosis correlates with a neutrophil-driven type I interferon (IFN) signature, but the cellular mechanisms underlying tuberculosis pathogenesis remain poorly understood. We...
8.
Kotov D, Lee O, Ji D, Jaye D, Suliman S, Gabay C, et al.
bioRxiv
. 2023 Nov;
PMID: 37961447
( ) causes 1.6 million deaths a year . However, no individual mouse model fully recapitulates the hallmarks of human tuberculosis disease. Here we report that a comparison across three...
9.
Lewis J, Cooper L, Jaye D, Pozdnyakova O
Mod Pathol
. 2023 Nov;
37(1):100373.
PMID: 37925056
The current flow cytometric analysis of blood and bone marrow samples for diagnosis of acute myeloid leukemia (AML) relies heavily on manual intervention in the processing and analysis steps, introducing...
10.
Lewis J, Cooper L, Jaye D, Pozdnyakova O
bioRxiv
. 2023 Oct;
PMID: 37808719
Current flow cytometric analysis of blood and bone marrow samples for diagnosis of acute myeloid leukemia (AML) relies heavily on manual intervention in both the processing and analysis steps, introducing...